A Potential Role for Daptomycin in Enterococcal Infections: What is the Evidence?

Overview

Journal J Antimicrob Chemother

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2010 Apr 6

PMID 20363805

Citations 29

Authors

Rafael Canton

Patricia Ruiz-Garbajosa

Ricardo L Chaves

Alan P Johnson

Affiliations

Soon will be listed here.

Abstract

Nosocomial infections caused by enterococci present a challenge for clinicians because treatment options are often limited due to the widespread occurrence of strains resistant to multiple antibiotics, including vancomycin. Daptomycin is a first-in-class cyclic lipopeptide that has proven efficacy for the treatment of Gram-positive infections. Although methicillin-resistant Staphylococcus aureus has been the most prominent target in the clinical development of daptomycin, this agent has demonstrated potent bactericidal activity in enterococcal infection models and has been used for the treatment of enterococcal infections in humans. In recent years, large-scale susceptibility studies have shown that daptomycin is active against >98% of enterococci tested, irrespective of their susceptibility to other antibacterial agents. This lack of cross-resistance reflects the fact that daptomycin has a mode of action distinct from those of other antibiotics, including glycopeptides. While there are limited data available from randomized controlled trials, extensive clinical experience with daptomycin in enterococcal infections (including bacteraemia, endocarditis, skin and soft tissue infections, bone and joint infections and urinary tract infections) has been reported. This growing body of evidence provides useful insights regarding the efficacy of daptomycin against enterococci in clinical settings.

Citing Articles

Chemoenzymatic Modification of Daptomycin: Aromatic Group Installation on Trp1.

Dimas D, Kumar V, Mandal P, Masterson J, Tonelli M, Singh S Chembiochem. 2024; 25(22):e202400503.

PMID: 39019798 PMC: 11576237. DOI: 10.1002/cbic.202400503.

Comparing antibiotic resistance and virulence profiles of , , and from environmental and clinical settings.

Denissen J, Havenga B, Reyneke B, Khan S, Khan W Heliyon. 2024; 10(9):e30215.

PMID: 38720709 PMC: 11076977. DOI: 10.1016/j.heliyon.2024.e30215.

Multidrug Resistance (MDR) and Collateral Sensitivity in Bacteria, with Special Attention to Genetic and Evolutionary Aspects and to the Perspectives of Antimicrobial Peptides-A Review.

Fodor A, Abate B, Deak P, Fodor L, Gyenge E, Klein M Pathogens. 2020; 9(7).

PMID: 32610480 PMC: 7399985. DOI: 10.3390/pathogens9070522.

Time-kill curves of daptomycin and Monte Carlo simulation for the treatment of bacteraemia caused by Enterococcus faecium.

Menezes B, Alves I, Staudt K, Beltrame B, Venz L, Michelin L Braz J Microbiol. 2019; 51(1):169-176.

PMID: 31845296 PMC: 7058735. DOI: 10.1007/s42770-019-00200-4.

Optimizing the Dosing Regimens of Daptomycin Based on the Susceptible Dose-Dependent Breakpoint against Vancomycin-Resistant Enterococci Infection.

Santimaleeworagun W, Changpradub D, Thunyaharn S, Hemapanpairoa J Antibiotics (Basel). 2019; 8(4).

PMID: 31795437 PMC: 6963552. DOI: 10.3390/antibiotics8040245.

References

Silverman J, Oliver N, Andrew T, Li T . Resistance studies with daptomycin. Antimicrob Agents Chemother. 2001; 45(6):1799-802. PMC: 90548. DOI: 10.1128/AAC.45.6.1799-1802.2001. View

Sader H, Moet G, Jones R . Update on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005-2007). J Chemother. 2009; 21(5):500-6. DOI: 10.1179/joc.2009.21.5.500. View

Zhanel G, Decorby M, Nichol K, Wierzbowski A, Baudry P, Karlowsky J . Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn Microbiol Infect Dis. 2008; 62(1):67-80. DOI: 10.1016/j.diagmicrobio.2008.04.012. View

Piper K, Steckelberg J, Patel R . In vitro activity of daptomycin against clinical isolates of Gram-positive bacteria. J Infect Chemother. 2005; 11(4):207-9. DOI: 10.1007/s10156-005-0395-x. View

Huen S, Hall I, Topal J, Mahnensmith R, Brewster U, Abu-Alfa A . Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant enterococcus peritonitis. Am J Kidney Dis. 2009; 54(3):538-41. DOI: 10.1053/j.ajkd.2008.12.017. View

Jorgensen J, Crawford S, Kelly C, Patterson J . In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods. Antimicrob Agents Chemother. 2003; 47(12):3760-3. PMC: 296189. DOI: 10.1128/AAC.47.12.3760-3763.2003. View

Cunha B, Mickail N, Eisenstein L . E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart Lung. 2007; 36(6):456-61. DOI: 10.1016/j.hrtlng.2007.02.012. View

Coque T, Willems R, Fortun J, Top J, Diz S, Loza E . Population structure of Enterococcus faecium causing bacteremia in a Spanish university hospital: setting the scene for a future increase in vancomycin resistance?. Antimicrob Agents Chemother. 2005; 49(7):2693-700. PMC: 1168696. DOI: 10.1128/AAC.49.7.2693-2700.2005. View

Gallagher J, Perez M, Marino E, LoCastro L, Abrardo L, MacDougall C . Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy. 2009; 29(7):792-9. DOI: 10.1592/phco.29.7.792. View

10.

Heikens E, Bonten M, Willems R . Enterococcal surface protein Esp is important for biofilm formation of Enterococcus faecium E1162. J Bacteriol. 2007; 189(22):8233-40. PMC: 2168697. DOI: 10.1128/JB.01205-07. View

11.

Rolston K, Segreti J, Lamp K, Friedrich L . Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med. 2007; 120(10 Suppl 1):S4-5. DOI: 10.1016/j.amjmed.2007.07.008. View

12.

Sader H, Watters A, Fritsche T, Jones R . Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis. 2007; 7:29. PMC: 1865382. DOI: 10.1186/1471-2334-7-29. View

13.

Mohr J, Friedrich L, Yankelev S, Lamp K . Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Int J Antimicrob Agents. 2009; 33(6):543-8. DOI: 10.1016/j.ijantimicag.2008.12.007. View

14.

Steenbergen J, Mohr J, Thorne G . Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J Antimicrob Chemother. 2009; 64(6):1130-8. DOI: 10.1093/jac/dkp346. View

15.

Alder J, Li T, Yu D, Morton L, Silverman J, Zhang X . Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection. Antimicrob Agents Chemother. 2003; 47(11):3561-6. PMC: 253759. DOI: 10.1128/AAC.47.11.3561-3566.2003. View

16.

Sandoe J, Wysome J, West A, Heritage J, Wilcox M . Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms. J Antimicrob Chemother. 2006; 57(4):767-70. DOI: 10.1093/jac/dkl013. View

17.

. EUCAST Technical Note on daptomycin. Clin Microbiol Infect. 2006; 12(6):599-601. DOI: 10.1111/j.1469-0691.2006.01455.x. View

18.

Owens Jr R, Lamp K, Friedrich L, Russo R . Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin. Am J Med. 2007; 120(10 Suppl 1):S6-12. DOI: 10.1016/j.amjmed.2007.07.009. View

19.

LaPlante K, Mermel L . In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains. Antimicrob Agents Chemother. 2009; 53(7):3166-9. PMC: 2704672. DOI: 10.1128/AAC.01642-08. View

20.

Snydman D, McDermott L, Jacobus N . Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves. J Chemother. 2006; 17(6):614-21. DOI: 10.1179/joc.2005.17.6.614. View